SIRT3 and Insulin resistance: The Sirt3 activator Oroxylin A and the histone acetyltransferase inhibitor CPTH2 obliterated (p < 0.05 vs. high insulin group) or overtly dampened insulin resistance-induced cardiomyocyte dysfunction and mitochondrial injury (aconitase activity) without eliciting any effects themselves.